<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682448</url>
  </required_header>
  <id_info>
    <org_study_id>06122201</org_study_id>
    <nct_id>NCT00682448</nct_id>
  </id_info>
  <brief_title>Metformin for the Prevention of the Metabolic Side-effects of Zyprexa</brief_title>
  <official_title>Metformin to Prevent the Metabolic Complications of Olanzapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that metformin co-administered with olanzapine will be well tolerated and
      associated with significantly less insulin resistance, weight gain and dyslipidemia as
      compared to olanzapine plus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased risk of metabolic complications with olanzapine therapy, relative to other
      antipsychotics, may lead clinicians to avoid its use, despite evidence of greater efficacy.
      These problems may also pose a therapeutic dilemma for patients who respond well to
      olanzapine. Metabolic complications negatively impact on morbidity and mortality, impair
      quality of life and increase illness relapse secondary to medication non-compliance. Thus
      far, no pharmacologic agent co-administered with olanzapine has proven effective at
      preventing these untoward effects. The present study proposes to examine the efficacy and
      safety of metformin to attenuate the metabolic side effects associated with olanzapine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Gain and Insulin Resistance</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dislipidemia, OGTT, Hemoglobin A1C</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Metabolic Complications</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Riomet</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Diabex</other_name>
    <other_name>Diaformin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo. Subjects will remain on placebo for 6 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of: Schizophrenia, Schizoaffective Disorder, Bipolar I or II or major
             depression with psychotic features who will be started on or who have just started
             taking Olanzapine (Zyprexa).

        Exclusion Criteria:

          -  Patients with either a history of diabetes mellitus or a baseline FBG&gt;126 or two
             random blood sugars of &gt; 200 or during a OGTT glucose level of &gt; 200 two hours after a
             glucose load of 50 grams. (All American Diabetes Association criteria for diabetes
             mellitus).

          -  Baseline liver function tests (SGOT, SGPT, AP) greater than 3X normal.

          -  Chronic alcoholism

          -  MDRD less than 60 ml/1.73 m2. Modification of Diet in Renal Disease (MDRD) Equation
             estimates the glomerular filtration rate as a measure of kidney function. This
             equation takes into account the plasma creatinine, age, race and gender, and is a more
             accurate estimation of glomerular filtration rate than serum creatinine alone.

          -  Patients with unstable medical problems, including cardiovascular instability or
             significant congestive heart failure (as determined by study investigators).

          -  Prolonged QTc greater than 430 ms on baseline EKG.

          -  History of lactic acidosis.

          -  History of hypoglycemia.

          -  Current treatment with metformin or other antidiabetic agents.

          -  Treatment with any antihyperlipidemic medication within 3 months of randomization.

          -  Treatment with olanzapine or clozapine within 3 months of randomization.

          -  Concurrent treatment with ziprasidone, risperidone, quetiapine or aripiprazole or any
             other neuroleptic medication.

          -  Concurrent use of OTC chromium, gymnema or cimetidine will be prohibited. Patient may
             discontinue these medications up to one day prior to randomization.

          -  Current treatment with corticosteroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey T Rado, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <disposition_first_submitted>November 29, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 12, 2012</disposition_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey Rado, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Olanzapine</keyword>
  <keyword>Zyprexa</keyword>
  <keyword>Weight Gain</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Metformin</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Depression</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Side effects</keyword>
  <keyword>Metabolic complications</keyword>
  <keyword>Prevention</keyword>
  <keyword>Treatment</keyword>
  <keyword>Metabolic side effects of olanzapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 15, 2016</submitted>
    <returned>April 13, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

